Statement of Changes in Beneficial Ownership (4)
24 February 2021 - 10:00AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Donaldson Michael Paul |
2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc.
[
SMMT
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Financial Officer |
|
(Last)
(First)
(Middle)
C/O SUMMIT THERAPEUTICS INC.,, ONE BROADWAY, 14TH FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/19/2021 |
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (right to buy) | $3.52 | 2/19/2021 | | D | | | 5110 (1) | (2) | 6/8/2030 | Common Stock | 5110 | (3) | 594890 | D | |
| Explanation of Responses: |
| (1) | Represents the forfeiture of performance-based stock options granted to the Reporting Person on June 8, 2020 that were eligible to vest based on certain performance conditions. Upon grant, the target vesting amount was reported in Table II of Form 3. On February 19, 2021, the Compensation Committee of the Board of Directors of the Issuer determined that, based on the Issuer's performance over the applicable performance period, 37,129 shares would vest and 5,110 shares would be forfeited. |
| (2) | As of February 19, 2021, a total of 79,368 shares have vested and 515,522 shares remain eligible to vest from this grant. |
| (3) | Not applicable. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Donaldson Michael Paul
C/O SUMMIT THERAPEUTICS INC.,
ONE BROADWAY, 14TH FLOOR
CAMBRIDGE, MA 02142 |
|
| Chief Financial Officer |
|
Signatures
|
| /s/ Michael Paul Donaldson, Attorney-in-Fact | | 2/23/2021 |
| **Signature of Reporting Person | Date |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024
